Treatment of Verrucous Carcinoma of the Lower Lip with Topical Imiquimod (Aldara®) and Debulking Therapy

Hyok Bu Kwon, M.D., Yun Seok Choi, M.D., Joon Ho Lee, M.D., Sang Yun Jin, M.D., Beom Joon Kim, M.D., Seung Ho Lee, M.D., Ai Young Lee, M.D.

Department of Dermatology, Dongguk University Ilsan Hospital, College of Medicine, Dongguk University, Goyang, 1 Chung-Ang University of Medicine, Seoul, Korea

Verrucous carcinoma is an unusual, non-metastasizing, distinct variant of squamous cell carcinoma composed of four subtypes according to the site of occurrence: oral type, anogenital type, plantar type, and other cutaneous sites. Oral type verrucous carcinoma usually shows slow progression with a low incidence of metastases. Treatment of verrucous carcinoma is challenging; multiple medical and surgical therapies are often attempted, with limited success. We reported on 2 cases of verrucous carcinoma of the lip treated with topical imiquimod and debulking therapy. (Ann Dermatol 23(S1) S68∼S71, 2011)

-Keywords- Lasers, gas; Cryotherapy; Imiquimod; Carcinoma, verrucous

INTRODUCTION

Verrucous carcinoma is an unusual, distinct variant of squamous cell carcinoma, which was first reported by Ackerman in 1948¹. Verrucous carcinomas consist of oral tumors on the buccal mucosa, which have been referred to as oral florid papillomatosis². These tumors may be clinically mistaken for giant warts, and both clinical and histological diagnosis must be established. Malignant transformation of verrucous carcinoma into squamous cell carcinoma has been reported in 30∼50% of cases³; however, no clear guidelines for effective and safe management of this disease are currently available. Here, we report on two cases of verrucous carcinoma of the lower lip, which were treated with a combination of topical imiquimod (Aldara®) and debulking therapy.

CASE REPORT

Case 1

A 70-year-old male patient presented with an extensive verrucous, hyperkeratotic tumor on the central aspect of his lower lip (Fig. 1A). The tumor had been growing for 1 month. The patient was a smoker and a social alcohol drinker. However, his history of trauma to the lesion was unremarkable and he had no past medical history or family history of similar lesions or other skin diseases. Physical examination revealed an exophytic verrucous yellowish-to-whitish tumor measuring approximately 4 cm in diameter. The patient complained of mild tenderness on the lesion and the tumor was firm upon palpation. No lymphadenopathy was detected on the neck or sublingual area.

Microscopic examination of a punch biopsy specimen revealed an endophytic epidermal proliferation with bulbous and blunted projections composed of large well-differentiated squamous epithelial cells extending into the reticular dermis (Fig. 2A). Cellular pleomorphism was minimal and mitotic activity was confined to the basal
Treatment of Verrucous Carcinoma of the Lower Lip with Topical Imiquimod (Aldara<sup>Ⓡ</sup>) and Debulking Therapy

Vol. 23, Suppl. 1, 2011

S69

Fig. 1. (A) Extensive verrucous, hyperkeratotic tumor on the central aspect of the lower lip. (B) After treatment, all skin lesions disappeared.

Fig. 2. (A) A biopsy specimen revealed the presence of an endophytic epidermal proliferation with bulbous, blunted projections composed of large, well-differentiated, squamous epithelial cells extending into the reticular dermis (H&E, ×20). (B) Cellular pleomorphism was minimal and mitotic activity was confined to the basal layer (H&E, ×200).

layer (Fig. 2B). Based on these findings, the patient was diagnosed with verrucous carcinoma. Carbon dioxide laser treatment was then performed following tumescent local anesthesia using lidocaine 0.2%.

After 10 days, the wound was completely epithelialized. At this point, topical treatment with imiquimod was started, with application of cream to the washed and dried tumor surface and then washed off 12 hours after application 3 times per week. After 4 weeks of treatment, the verrucous plaques had decreased in size; however, formation of mild erythema and crust with oozing was observed on the tumor and the patient complained of local pain. Therefore, application of imiquimod was then stopped and the patient received oral administration of analgesics and topical application of antibiotics to the tumor. Over a 4-week period of treatment with analgesics and topical antibiotics, local pain, erythema, and crust slowly disappeared. At this point, administration of imiquimod was started again, with application of treatment 3 times per week over a period of 4 weeks. Treatment was well tolerated by the patient and no unwanted side effects occurred. After 3 months of treatment, the tumor was clinically resolved (Fig. 1B).

Case 2

A 75-year-old male developed painful hyperkeratotic plaques on the right aspect of his lower lip, which had persisted for more than 6 months (Fig. 3A). Prior to his visit to our hospital, the patient had been diagnosed with verrucous carcinoma based on the results of a histologic examination conducted at another hospital. Because the lesions progressed in size after the biopsy, he visited our hospital without treatment. The patient was a heavy smoker, but had no previous history of trauma or exposure to radiation.

Physical examination revealed verrucous plaques with fissuring on the right aspect of the lower lip. Microscopically, the specimen showed marked parakeratosis, neoplastic proliferation, and downward invasion of epidermal keratinocytes with a blunt border and a pushed-down, bulldozing appearance. Inflammatory cell infiltrates surrounding the tumor were also observed (Fig. 4).
Fig. 3. (A) Verrucous plaques with fissuring on the right aspect of the lower lip. (B) After treatment, all skin lesions disappeared.

DISCUSSION

The natural history of verrucous carcinoma of the skin is marked by slow growth of a well-circumscribed tumor, which often shows a papillomatous surface. The tumor is typically located on the sole of the foot or elsewhere on the lower extremities; however, other locations, including the buttocks or the palm of the hand, have been reported4. In 1981, Diaz-Pérez et al.5 first reported lip verrucous carcinoma similar to the cases described. In addition, Krutchkoff et al.6 reported that verrucous carcinoma on the lip constituted only 2.8% of all oral neoplasms. Although the cause of verrucous carcinoma is still unclear, it has been reported to have an association with earlier injuries and scars, as well as with chronic inflammation3,7. Chewing tobacco, betel nuts, and dipped snuffs are also associated with development of verrucous carcinoma of the lip2. Although the role of human papillomaviruses in development of verrucous carcinoma of the skin is still unclear, DNA of human papillomaviruses has been identified in such carcinomas8,9. However, in a clinicopathologic study, Kao et al.4 were unable to demonstrate the presence of virus particles in specimens.

Treatment modalities for verrucous carcinoma include surgical excision, chemotherapy, cryosurgery, intralesional or iontophoretic methods, systemic retinoid therapy, and radiotherapy. Surgical excision is the treatment of choice for verrucous carcinoma. However, incomplete resection can result in accelerated tumor growth; therefore, care must be taken to fully remove all parts of the tumor. In addition, when surgical excision is considered, the size of the defect is often the most important factor because it is usually a strong indicator of the optimal method of reconstruction10. A defect of approximately 30% of the upper or lower lip can be reconstructed by the primary closure due to the great elasticity of the lip11. In our case, total excision was not performed because the tumor encompassed greater than 30% of the lower lip. If a wide excision had been performed in these cases, the defect would have required more complicated reconstructive...
treatment, such as flap surgery.

Imiquimod, a toll-like receptor 7 agonist, is a patient-applied cream that is used in treatment of certain diseases of the skin, including various forms of skin cancer (basal cell carcinoma, Bowen’s disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis) as well as genital warts\textsuperscript{11-16}. The exact mechanism of imiquimod is not known; however, its effects are thought to be a result of augmentation of immune response through induction of interferon alfa\textsuperscript{17}.

Imiquimod has been used in conjunction with a carbon dioxide laser for treatment of perianal verrucous carcinoma\textsuperscript{18}. In addition, Schalock et al.\textsuperscript{19} described 2 cases of verrucous carcinoma of the foot, which were treated with imiquimod for more than 1 year.

We did not perform a biopsy after treatment; therefore, we cannot confirm that the tumor has been resolved. However, no further relapse has been observed for 30 months since the last treatment.

In summary, here we describe two cases of rapidly growing oral verrucous carcinoma of the lip, which were treated with a combination of topical imiquimod and debulking therapy. There was no recurrence of the carcinoma for more than 3 months and the cosmesis was excellent. Taken together, these findings suggest that combination therapy of topical imiquimod and a debulking method may be useful for treatment of some cases of verrucous carcinoma.

REFERENCES

1. Ackerman LV. Verrucous carcinoma of the oral cavity. Surgery 1948;23:670-678.
2. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Gldsmith LA, Katz SI, et al. Fitzpatrick’s dermatology in general medicine. 6th ed. New York: Mcgraw-Hill, 2003:742-743.
3. Creasman C, Haas PA, Fox TA Jr, Balazs M. Malignant transformation of anorectal giant condyloma acuminatum (Buschke-Loewenstein tumor). Dis Colon Rectum 1989;32:481-487.
4. Kao GF, Graham JH, Helwig EB. Carcinoma cuniculatum (verrucous carcinoma of the skin): a clinicopathologic study of 46 cases with ultrastructural observations. Cancer 1982;49:2395-2403.
5. Diaz-Pérez JL, Moreno J, Burgos J. Ackerman’s verrucous carcinoma on the lower lip. Med Cutan Ibero Lat Am 1981;9:105-110.
6. Krutchkoff DJ, Chen JK, Eisenberg E, Katz RV. Oral cancer: a survey of 566 cases from the University of Connecticut Oral Pathology Biopsy Service, 1975-1986. Oral Surg Oral Med Oral Pathol 1990;70:192-198.
7. Zielonka E, Goldschmidt D, de Fontaine S. Verrucous carcinoma or epithelioma cuniculatum plantare. Eur J Surg Oncol 1997;23:86-87.
8. Garven TC, Thelmo WL,Victor J, Pertschuk L. Verrucous carcinoma of the leg positive for human papillomavirus DNA 11 and 18: a case report. Hum Pathol 1991;22:1170-1173.
9. Knobler RM, Schneider S, Neumann RA, Bodemer W, Radlwiimmer B, Aberer E, et al. DNA dot-blott hybridization implicates human papillomavirus type 11-DNA in epithelioma cuniculatum. J Med Virol 1989;29:33-37.
10. Stephen JM, Vincent RH. Plastic surgery. 6th ed. Philadelphia: Elsevier Inc, 2006:799-800.
11. Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-813.
12. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol 2001;44:462-470.
13. Kaspari M, Gutzmer R, Kiehl P, Dumke P, Kapp A, Brodersen JP. Imiquimod 5% cream in the treatment of human papillomavirus-16-positive erythroplasia of Queyrat. Dermatology 2002;205:67-69.
14. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-556.
15. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002;205:135-138.
16. Tyring S. Imiquimod applied topically: a novel immune response modifier. Skin Therapy Lett 2001;6:1-4.
17. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg 2004;30:1101-1112.
18. Heinzerling LM, Kempf W, Kamarashev J, Hafner J, Nestle FO. Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation. Dermatology 2003;207:119-122.
19. Schalock PC, Kornik RJ, Baughman RD, Chapman MS. Treatment of verrucous carcinoma with topical imiquimod. J Am Acad Dermatol 2006;54(5 Suppl):S233-235.